$WVE Cashflow Statement | Understand Stock

$WVE

$3.21 +$0.03 (0.94%) Close

$WVE Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities
Net loss
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Amortization of right-of-use assets
Depreciation of property and equipment
Share-based compensation expense
Loss on disposal of property and equipment
Changes in operating assets and liabilities:
Accounts receivable
Prepaid expenses
Other assets
Accounts payable
Accrued expenses and other current liabilities
Deferred revenue
Operating lease liabilities
Other non-current liabilities

Net cash used in operating activities
Cash flows from investing activities
Purchases of property and equipment
Proceeds from the sale of property and equipment
Purchase of short-term investments
Proceeds from the maturity of short-term investments
Net cash used in investing activities

Cash flows from financing activities
Proceeds from the issuance of ordinary shares as a part of the September 2024 Offering, net of offering costs
Proceeds from issuance pre-funded warrants, net of offering costs
June 2022 Offering
September 2024 Offering
December 2025 Offering
Total proceeds from issuance pre-funded warrants, net of offering costs

Proceeds from issuance of ordinary shares pursuant to the GSK Collaboration Agreement
Proceeds from issuance of ordinary shares pursuant to the at-the-market equity program, net
Proceeds from the exercise of share options
Proceeds from the ESPP
Net cash provided by financing activities
Effect of foreign exchange rates on cash
Net increase in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash, beginning of period
Cash, cash equivalents and restricted cash, end of period
Supplemental disclosure of cash flow information:
Offering costs in accounts payable at period end
Increase in operating lease right-of-use assets and lease liabilities related to new lease

Comments